Bernstein Lifts PT on Arrowhead Pharmaceuticals (ARWR) Following Biotech’s Solid Start to 2026
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of the best medical stocks to invest in according to billionaires. Arrowhead Pharmaceuticals, Inc.
Posts Tagged ‘NASDAQ:ARWR’
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2026 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2026 Earnings Call Transcript May 7, 2026Arrowhead Pharmaceuticals, Inc. beats earnings expectations.
Arrowhead (ARWR) Rated Buy on Metabolic Pipeline Potential
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) ranks among the most profitable biotech stocks to buy now. Following comments on Arrowhead Pharmaceuticals Inc.
10 Most Profitable Biotech Stocks to Buy Now
Following a turbulent year for the markets in general and biotech in particular, the industry made a notable recovery, surpassing both the S&P 500 and the broader market index...
Arrowhead Pharmaceuticals Inc. (ARWR): Billionaire Ken Fisher Bets Big on Pharma
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a relatively recent addition to the 13F portfolio of Fisher Asset Management.
Billionaire Ken Fisher’s 15 Most Notable Moves for 2026
For many Wall Street investors, it is their first time navigating market uncertainty at a time of geopolitical upheaval.
Arrowhead (ARWR) FQ1 2026 Revenue Hits $264M as REDEMPLO Approval Marks Commercial Shift
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) is one of the best multibagger stocks to invest in according to billionaires.
12 Best Multibagger Stocks to Invest In According to Billionaires
On March 11, Tom Lee of Fundstrat joined 'Closing Bell' on CNBC to discuss his market outlook amid rising oil prices and sector volatility.
Morgan Stanley Notes 2026 Sales From Arrowhead Pharmaceuticals, Inc. (ARWR)’s Familial Chylomicronemia Syndrome Likely Limited
TheFly reported on February 6 that Morgan Stanley lowered its price target for ARWR to $78 from $81 and kept an Equal Weight rating.
15 Innovative Healthcare Stocks to Buy According to Analysts
Over the last two years, artificial intelligence has propelled global financial markets into a boom, with stocks reaching all-time highs.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2026 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2026 Earnings Call Transcript February 5, 2026Arrowhead Pharmaceuticals, Inc. misses on earnings expectations.
Piper Sandler Highlights Arrowhead Pharmaceuticals, Inc. (ARWR) Pipeline With Upcoming Phase III Hypertriglyceridemia Data
TheFly reported on January 13 that Piper Sandler lifted its price target on ARWR to $110 from $100, and reiterated an Overweight rating.
Arrowhead Pharmaceuticals, Inc. (ARWR): A Bull Case Theory
We came across a bullish thesis on Arrowhead Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on ARWR.
Piper Sandler Maintains an Overweight rating on Arrowhead Pharmaceuticals, Inc. (ARWR)
On December 17, 2025, TheFly reported that Piper Sandler maintained its Overweight rating for Arrowhead Pharmaceuticals, Inc.
Arrowhead (ARWR) Hits 3-Year High on Strong Earnings, FDA Approval
Arrowhead Pharmaceuticals soared to a new three-year high on Wednesday, as investors took heart from its impressive earnings performance for the full fiscal year, alongside the...
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2025 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2025 Earnings Call Transcript November 25, 2025Arrowhead Pharmaceuticals, Inc. misses on earnings expectations.
11 Best Stocks to Buy for the Next 3 Months According to Hedge Funds
On September 6, Rebecca Patterson, Chief Investment Strategist at Bridgewater Associates, appeared in an interview on CNBC to discuss the current US economy.
Arrowhead (ARWR) Climbs 24.9% on $100-Million Licensing Revenue
Arrowhead Pharmaceuticals soared by 24.9 percent week-on-week as investors welcomed the company’s receipt of $100 million in payments from Sarepta Therapeutics Inc.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call.
Arrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough Deal
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a biotechnology company specializing in RNA interference (RNAi) therapeutics for diseases with high unmet medical needs.
11 Best Future Stocks to Buy Now
Over the past year, investors have poured money into cutting-edge technologies like artificial intelligence and electric cars.
Arrowhead Pharma (ARWR) Shares Dragged by Sarepta Concerns
Arrowhead Pharmaceuticals fell by 12.23 percent on Monday to close at $14.71 apiece as investors turned cautious amid regulatory troubles faced by one of its partners, Sarepta...
Jim Cramer on Arrowhead Pharmaceuticals (ARWR): “It Doesn’t Make Any Money”
We recently published a list of Jim Cramer’s Thoughts on These 12 Stocks. In this article, we are going to take a look at where Arrowhead Pharmaceuticals, Inc.
Jim Cramer’s Thoughts on These 12 Stocks
On Tuesday’s episode of Mad Money, host Jim Cramer expressed concern over how President Donald Trump's actions have been impacting the stock market as he pointed out the confusion...
Arrowhead Pharmaceuticals, Inc. (ARWR)’s ARO-ALK7 Enters Phase 1/2a Study
Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2025 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2025 Earnings Call Transcript May 12, 2025Arrowhead Pharmaceuticals, Inc. beats earnings expectations.
Top 11 Small Cap Stocks to Buy with Biggest Upside Potential
On April 24, Jill Carey Hall, BofA Securities head of U.S. small/mid-cap strategy, appeared on 'Closing Bell' to talk about the impact of tariffs on small caps.
12 Most Oversold Healthcare Stocks to Buy Now
Healthcare costs and spending have been rising in the US.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2025 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2025 Earnings Call Transcript February 10, 2025Arrowhead Pharmaceuticals, Inc. misses on earnings expectations.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2024 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2024 Earnings Call Transcript November 26, 2024Arrowhead Pharmaceuticals, Inc. misses on earnings expectations.
12 NASDAQ Stocks with Biggest Upside Potential According to Analysts
Potomac Wealth Advisors president Mark Avallone joined CNBC's 'The Exchange' on November 16 to discuss where he sees investing opportunities following Trump's election.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2024 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2024 Earnings Call Transcript August 8, 2024Arrowhead Pharmaceuticals, Inc. misses on earnings expectations.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2024 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.01634 EPS, expectations were $-0.06. Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2024 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.03 EPS, expectations were $-0.78.
5 Most Promising Biotech Stocks to Buy According to Analysts
In this article, we will take a look at the 5 most promising biotech stocks to buy according to analysts.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. Throughout today's recorded presentation, all participants will be in a listen-only.
5 Biotech Stocks with Biggest Upside
In this article, we discuss 5 biotech stocks with biggest upside.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. Throughout today's recorded presentation, all participants will be in a listen-only.
15 Worst Performing Biotech Stocks in 2023
In this article, we discuss 15 worst performing biotech stocks in 2023.
Does Arrowhead Pharmaceuticals (ARWR) Have a Long Runway for Growth?
Baron Funds, an investment management company, released its “Baron Opportunity Fund” first quarter 2023 investor letter. A copy of the same can be downloaded here.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call.
12 High Growth Healthcare Stocks to Buy
The healthcare sector proved its mettle in 2022.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2022 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to Arrowhead Pharmaceuticals Conference Call. Throughout today's recorded presentation, all participants will be in a listen-only mode.
Baron Funds Sold Arrowhead Pharmaceuticals (ARWR) to Reallocate to Higher Conviction Ideas
Baron Funds, an asset management company, released its “Baron Global Advantage Fund” second quarter 2022 investor letter. A copy of the same can be downloaded here.
Baron Funds: “We Retain Conviction in Arrowhead (ARWR)”
Baron Funds, an asset management firm, published its “Baron Opportunity Fund” first quarter 2022 investor letter – a copy of which can be downloaded here.
Top 5 Stock Picks of Frank Fu’s CaaS Capital
In this article, we discuss the top 5 stock picks of Frank Fu's CaaS Capital.
Should I Avoid Arrowhead Pharmaceuticals Inc. (ARWR)?
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end...
Is it a Good Thing to Keep Your Arrowhead Pharmaceuticals (ARWR) Shares?
Carillon Tower Advisers, an investment management firm, published its “Carillon Eagle Small Cap Growth Fund” third quarter 2021 investor letter – a copy of which can be ...
Hedge Fund Resource Center
